Table 5.

Severity of side effects reported by Phase IIIA respondents, before stopping and after restarting treatment.

Variables	N experienced before stopping treatment	% experienced before stopping treatment	$\overline{\mathrm{X}}$ severity score before stopping treatment	N experienced after restarting treatment	% experienced after restarting treatment	$\overline{\mathrm{X}}$ severity score after restarting treatment	Difference of $\overline{\mathrm{X}}$ severity score after restarting treatment	% difference of $\overline{\mathrm{X}}$ severity score after restarting treatment
Side effect
Feeling sad	85	(53)	2.14	86	(54)	2.73	0.59	(28)
Feeling distressed (upset)	83	(52)	2.34	84	(53)	2.90	0.57	(24)
Anxiety	84	(53)	2.31	91	(57)	2.80	0.49	(21)
Headaches	81	(51)	2.14	77	(48)	2.48	0.34	(16)
Lack of appetite	70	(44)	1.53	66	(42)	1.77	0.24	(16)
Disturbed sleep	98	(62)	2.80	96	(60)	3.03	0.24	(08)
Diarrhoea	89	(56)	2.12	81	(51)	2.31	0.19	(09)
Feeling of malaise (not feeling well)	88	(55)	2.63	86	(54)	2.79	0.17	(06)
Hair loss	89	(56)	2.31	76	(48)	2.46	0.15	(06)
Bruising	77	(48)	1.57	74	(47)	1.69	0.12	(07)
Difficulty thinking clearly	89	(56)	2.44	92	(58)	2.53	0.09	(04)
Vomiting	73	(46)	1.48	63	(40)	1.57	0.09	(06)
Nausea	88	(55)	2.38	82	(52)	2.46	0.09	(04)
Menstrual cycle issues	69	(43)	1.83	55	(35)	1.85	0.03	(02)
Shortness of breath	95	(60)	2.44	80	(50)	2.46	0.02	(01)
Pain	89	(56)	2.72	79	(50)	2.72	0.00	(0)
Fatigue (tiredness)	125	(79)	3.30	121	(76)	3.31	0.00	(0)
Dry mouth	81	(51)	2.22	78	(49)	2.22	0.00	(0)
Rash or skin change	95	(60)	2.69	82	(52)	2.67	−0.02	−(01)
Numbness or tingling	90	(57)	2.34	74	(47)	2.31	−0.03	−(01)
Remembering things	94	(59)	2.54	83	(52)	2.48	−0.06	−(02)
Eye bleeds	90	(57)	1.86	77	(48)	1.77	−0.09	−(05)
Swelling of hands, feet, abdomen, and around eyes	101	(64)	2.86	91	(57)	2.65	−0.21	−(07)
Skin pigment changes	84	(53)	2.52	70	(44)	2.29	−0.24	−(09)
Muscle soreness or cramping	113	(71)	3.25	103	(65)	2.97	−0.28	−(09)
Other	16	(10)	2.63	14	(09)	1.50	−1.13	−(43)